Anal Gland Sacculectomy Dog Surgery

This is a great topic, as the decision to perform an anal sacculectomy involves balancing a significant quality-of-life improvement against a non-zero risk of a serious complication.

Here's my approach to these cases:

Indications & Decision Making:
Surgery is reserved for cases where medical management has failed or is no longer practical. This includes:

Recurrent Sacculitis/Impaction: If a dog requires manual expression more frequently than every 4-6 weeks, or has recurrent infections despite appropriate management, the benefit of surgery often outweighs the risks.

Abscessation/Rupture: A single abscess can sometimes be managed medically, but recurrence is common. An abscess is a strong indication for sacculectomy once the acute inflammation is controlled.

Neoplasia: Any firm, non-expressible mass associated with the anal sac should be considered a potential apocrine gland anal sac adenocarcinoma (AGASACA) until proven otherwise. This is an absolute indication for surgery.

Surgical Technique:
My preference is the closed technique. I find it provides the cleanest dissection and theoretically lowers the risk of leaving secretory epithelium behind, which can lead to draining fistulas. The key is meticulous, sharp-blunt dissection directly on the sac wall to separate it from the fibers of the external anal sphincter (EAS). The open technique, where the sac is incised, can be useful if the sac has ruptured and landmarks are obscured, but the risk of contamination is higher.

Risk of Fecal Incontinence:
This is the most critical conversation to have with the owner. The risk stems from iatrogenic damage to the EAS or, more significantly, the caudal rectal nerve. While the incidence of permanent incontinence is low (1-3% in most studies), transient incontinence or changes in fecal control are more common in the immediate post-operative period. Meticulous technique is everything here. I emphasize to owners that while I take every precaution, the risk is never zero.

Post-Operative Management:

E-collar: Non-negotiable to prevent self-trauma.

Pain Management: Multimodal analgesia is key. An NSAID combined with gabapentin is a good starting point.

Stool Softeners: I start every patient on lactulose or Miralax for 7-10 days to minimize straining during defecation.

Site Care: Warm compresses can help with swelling. Owners should monitor for excessive swelling, discharge, or signs of dehiscence.

For the crucial topic of staging and managing AGASACA, that falls squarely in the oncology domain. I perform the surgery, but the systemic workup and long-term plan are driven by their findings. I'll turn it over to Dr. Torres for that part of the discussion.

Dr. Torres, can you outline the staging process for a suspected AGASACA?

🧫 Dr. Rachel Torres — Veterinary Oncologist

James will cover the surgical details, which are paramount for local control. From my perspective, the key is what happens before a scalpel ever touches the patient, especially when we suspect apocrine gland anal sac adenocarcinoma (ASACA). A thorough workup is non-negotiable.

First, any middle-aged to older dog presenting with PU/PD needs a rectal exam. About 25-50% of ASACA cases present with paraneoplastic hypercalcemia due to PTHrP production, so this should be a primary differential.

Staging for ASACA is critical and includes:

Minimum Database: CBC, chemistry (with ionized calcium), and UA.

Regional Lymph Node Assessment: The sublumbar (medial iliac) lymph nodes are the primary site of metastasis. Abdominal ultrasound is essential to evaluate their size and architecture, and FNA should be performed if they appear abnormal. For surgical planning, contrast-enhanced CT is now the gold standard to assess node involvement and vascular invasion.

Distant Metastasis Screen: 3-view thoracic radiographs are mandatory to rule out pulmonary metastasis.

Prognosis and Adjuvant Therapy:
The goal of surgery is complete local excision, but the decision for adjuvant therapy hinges on staging.
* Prognostic Factors: Tumor size (<2.5 cm is favorable), lymph node status, and presence of hypercalcemia all influence survival.
* Treatment: Even with sublumbar lymph node metastasis, surgery (including lymphadenectomy) is still indicated and improves survival time. Following surgery, adjuvant chemotherapy with carboplatin or mitoxantrone is recommended for patients with metastatic disease or high-risk primary tumors. Toceranib (Palladia) is also showing promise in this setting.

With surgery alone, MST is typically 12-15 months. By adding chemotherapy for metastatic or high-risk disease, we can extend that to a median of 15-24 months of good quality life. The bottom line is that we can't make an informed treatment plan or give an accurate prognosis without a complete stage.